Cytek Biosciences Is A Speculative Buy On Recurring Revenue Growth
Source: SeekingAlpha
2025-11-20 05:49:35 ET
...
Read the full article on Seeking Alpha
For further details see:
Cytek Biosciences Is A Speculative Buy On Recurring Revenue Growth
Cytek Biosciences Inc.
NASDAQ: CTKB
CTKB Trading
-2.82% G/L:
$3.97 Last:
362,062 Volume:
$4 Open:
CTKB Latest News
March 09, 2026 05:00:00 pm
Cytek® Biosciences Celebrates One Year of Operations at Singapore Facility, Accelerating Growth and Regional Impact
February 26, 2026 04:05:00 pm
Cytek Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook
CTKB Stock Data
$553,654,714
114,656,393
9.13%
48
N/A
Biotechnology & Life Sciences
Healthcare
US
Fremont
